Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering

The new drug for type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner. In addition to glucose control, the management of coronary...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Med Res
Päätekijät: Yanai, Hidekatsu, Katsuyama, Hisayuki, Hamasaki, Hidetaka, Adachi, Hiroki, Moriyama, Sumie, Yoshikawa, Reo, Sako, Akahito
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elmer Press 2016
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676340/
https://ncbi.nlm.nih.gov/pubmed/26668677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2385w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia